EBERCONAZOLE MARKET

INTRODUCTION

 Eberconazole is a highly effective antifungal agent. A 1% concentration is commonly used in a topical cream. It can be used to treat skin infections such as dermatophytosis, candidiasis, and pityriasis.

This medicine is a broad-spectrum imidazole derivative that is regarded as a safe therapeutic option for dermatophytosis. It possesses fungicidal characteristics that impede fungal growth by altering the cell membranes of the fungi.

If allergic to any of its constituents or a similar medicine, it's recommended to discontinue. This cream can be used at any time of day, regardless of mealtime. The dosage and duration of treatment are determined by the severity and spread of the skin problem.

The information is based on the medicine's salt content. The medicine's uses and effects may differ from person to person. Before using this medication, it is best to check with an Internal Medicine Specialist.

EBERCONAZOLE MARKET SIZE AND FORECAST

The Global EBERCONAZOLE market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

EBERCONAZOLE MARKET RECENT DEVELOPMENT

Eberconazole 1% cream is an effective and safe alternative for dermatophytosis treatment: multicenter, randomised, double-blind, comparative trial with miconazole 2% cream.

Eberconazole is a topical, broad-spectrum imidazole derivative that is beneficial in the treatment of dermatophytoses, candidiasis, and pityriasis. In prior trials, it outperformed clotrimazole in the treatment of dermatophytoses.

The goal of this study was to compare the efficacy of eberconazole 1% cream to miconazole 2% cream in treating dermatophytoses.

In a multicenter, double-blind, randomised experiment, 653 patients with dermatophytoses were randomly assigned to either eberconazole 1% cream every 12 hours or miconazole 2% cream every 12 hours for 4 weeks.

Treatment efficacy was determined by calculating the percentage of successful responses after 4 weeks using mycologic and clinical data.

The trial included 653 patients, 360 of whom had positive baseline mycologic cultures and were included in the efficacy assessment. Clinical effectiveness was demonstrated in 76.1% of eberconazole patients and 75.0% of miconazole patients. The rate of treatment-related adverse events was 0.91% for eberconazole and 0.92% for miconazole, with none being serious and all being local and temporary.

Eberconazole 1% cream is an excellent treatment for dermatophyte fungal infections, with a good safety and tolerability profile, and can be considered a good choice for dermatophytosis treatment.

EBERCONAZOLE MARKET COMPANY PROFILES

• Pfizer Inc.
• GlaxoSmithKline
• IntelGenx Technologies Corp.
• Ipsen S.A.
• Novartis AG

THIS EBERCONAZOLE MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many  EBERCONAZOLE are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global  EBERCONAZOLE and key vendor selection criteria
3. Where is the  EBERCONAZOLE manufactured? What is the average margin per unit?
4. Market share of Global  EBERCONAZOLE market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global  EBERCONAZOLE in-house
6. key predictions for next 5 years in Global  EBERCONAZOLE market
7. Average B-2-B  EBERCONAZOLE market price in all segments
8. Latest trends in  EBERCONAZOLE market, by every market segment
9. The market size (both volume and value) of the  EBERCONAZOLE market in 2024-2030 and every year in between?
10. Production breakup of  EBERCONAZOLE market, by suppliers and their OEM relationship